^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | zorifertinib (AZD3759) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.
Published date:
05/25/2023
Excerpt:
IC PFS, ORR, and DoR with AZD3759 were all superior vs the control group...First-line AZD3759 demonstrated superior systemic and IC antitumor efficacy compared with first generation EGFR TKIs in pts with EGFRm+ NSCLC and CNS metastasis.
DOI:
10.1200/JCO.2023.41.16_suppl.9001
Trial ID:
Source:
Title:
20P - Efficacy and safety of AZD3759 in previously untreated EGFR-mutant non-small-cell lung cancer with central nervous system metastases in a multi-center, phase 2 umbrella trial (CTONG1702)
Published date:
03/23/2023
Excerpt:
We initiated an umbrella trial (CTONG1702), in the 8th arm to access the efficacy and safety of AZD3759, an EGFR-TKI with high capability to penetrate the blood-brain barrier, in untreated EGFR-mutant NSCLC with brain or leptomeningeal metastases. Patients received AZD3759 200 mg or 300 mg BID....This is the first report to present phase II study outcome of AZD3759 with promising efficacy and tolerable safety in the selected population with CNS metastases.
Trial ID:
